Clinical Trial Update: A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating CHO-H01 as a single agent or in combination with lenalidomide for refractory or relapsed Non-Hodgkin lymphoma is currently…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• CHO-H01
• Revlimid (lenalidomide)

Snippet

Sponsor: Cho Pharma Inc. | Conditions: Non-Hodgkin Lymphoma | Phase 1, Phase 2 | Status: RECRUITING